ES2347840T3 - Il-17rcx4 soluble y procedimiento de utilizacion en la inflamacion. - Google Patents
Il-17rcx4 soluble y procedimiento de utilizacion en la inflamacion. Download PDFInfo
- Publication number
- ES2347840T3 ES2347840T3 ES07863316T ES07863316T ES2347840T3 ES 2347840 T3 ES2347840 T3 ES 2347840T3 ES 07863316 T ES07863316 T ES 07863316T ES 07863316 T ES07863316 T ES 07863316T ES 2347840 T3 ES2347840 T3 ES 2347840T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- disease
- inflammatory
- human
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 48
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title abstract description 58
- 102000013691 Interleukin-17 Human genes 0.000 claims abstract description 389
- 108050003558 Interleukin-17 Proteins 0.000 claims abstract description 375
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 163
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 145
- 229920001184 polypeptide Polymers 0.000 claims description 142
- 238000011282 treatment Methods 0.000 claims description 47
- 230000002757 inflammatory effect Effects 0.000 claims description 46
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 42
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 41
- 238000004519 manufacturing process Methods 0.000 claims description 40
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 claims description 34
- 208000006673 asthma Diseases 0.000 claims description 31
- 201000004681 Psoriasis Diseases 0.000 claims description 28
- 108020001507 fusion proteins Proteins 0.000 claims description 26
- 102000037865 fusion proteins Human genes 0.000 claims description 26
- 208000027866 inflammatory disease Diseases 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 23
- 206010003246 arthritis Diseases 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 17
- 201000008937 atopic dermatitis Diseases 0.000 claims description 17
- 201000006417 multiple sclerosis Diseases 0.000 claims description 16
- 208000037487 Endotoxemia Diseases 0.000 claims description 13
- 208000037976 chronic inflammation Diseases 0.000 claims description 12
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 11
- 102100033454 Interleukin-17F Human genes 0.000 claims description 11
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 10
- 206010040070 Septic Shock Diseases 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 8
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 8
- 210000002345 respiratory system Anatomy 0.000 claims description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- LMUISDJVRQDLEK-UHFFFAOYSA-N 6,7-dichloro-1-[(3,4-dimethoxyphenyl)methyl]isoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(Cl)=C(Cl)C=C12 LMUISDJVRQDLEK-UHFFFAOYSA-N 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 102100035012 Interleukin-17 receptor C Human genes 0.000 abstract description 184
- 101710186068 Interleukin-17 receptor C Proteins 0.000 abstract description 179
- 241000282414 Homo sapiens Species 0.000 abstract description 107
- 201000010099 disease Diseases 0.000 abstract description 82
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 82
- 102000004127 Cytokines Human genes 0.000 abstract description 80
- 108090000695 Cytokines Proteins 0.000 abstract description 80
- 230000000694 effects Effects 0.000 abstract description 53
- 230000003472 neutralizing effect Effects 0.000 abstract description 24
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000000903 blocking effect Effects 0.000 abstract description 7
- 230000003042 antagnostic effect Effects 0.000 abstract description 6
- 230000001603 reducing effect Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 290
- 108090000623 proteins and genes Proteins 0.000 description 114
- 108020004414 DNA Proteins 0.000 description 106
- 108020003175 receptors Proteins 0.000 description 105
- 102000005962 receptors Human genes 0.000 description 104
- 238000009739 binding Methods 0.000 description 82
- 230000027455 binding Effects 0.000 description 81
- 102000004169 proteins and genes Human genes 0.000 description 80
- 230000014509 gene expression Effects 0.000 description 77
- 235000018102 proteins Nutrition 0.000 description 76
- 239000003446 ligand Substances 0.000 description 57
- 241000699670 Mus sp. Species 0.000 description 51
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 45
- 210000001519 tissue Anatomy 0.000 description 45
- 239000000203 mixture Substances 0.000 description 43
- 239000005557 antagonist Substances 0.000 description 42
- 210000001744 T-lymphocyte Anatomy 0.000 description 41
- 102000004554 Interleukin-17 Receptors Human genes 0.000 description 39
- 108010017525 Interleukin-17 Receptors Proteins 0.000 description 39
- 108091034117 Oligonucleotide Proteins 0.000 description 37
- 239000002502 liposome Substances 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 34
- 239000013598 vector Substances 0.000 description 34
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 30
- 210000002414 leg Anatomy 0.000 description 30
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 28
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 28
- 239000002953 phosphate buffered saline Substances 0.000 description 28
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 239000013604 expression vector Substances 0.000 description 27
- 241001529936 Murinae Species 0.000 description 26
- 101001019602 Homo sapiens Interleukin-17 receptor C Proteins 0.000 description 25
- 239000012634 fragment Substances 0.000 description 25
- 108090001005 Interleukin-6 Proteins 0.000 description 24
- 102000004889 Interleukin-6 Human genes 0.000 description 24
- 102000053162 human IL17A Human genes 0.000 description 24
- 230000001105 regulatory effect Effects 0.000 description 24
- 239000011780 sodium chloride Substances 0.000 description 24
- 239000007924 injection Substances 0.000 description 23
- 238000002347 injection Methods 0.000 description 23
- 230000001404 mediated effect Effects 0.000 description 23
- 230000004913 activation Effects 0.000 description 22
- 108020004999 messenger RNA Proteins 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 21
- 238000006386 neutralization reaction Methods 0.000 description 21
- 230000003248 secreting effect Effects 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 21
- 239000006228 supernatant Substances 0.000 description 21
- 108010076504 Protein Sorting Signals Proteins 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 20
- 210000001165 lymph node Anatomy 0.000 description 20
- 230000011664 signaling Effects 0.000 description 20
- 230000001225 therapeutic effect Effects 0.000 description 20
- 238000003556 assay Methods 0.000 description 19
- 239000002609 medium Substances 0.000 description 19
- 241000588724 Escherichia coli Species 0.000 description 18
- 206010009887 colitis Diseases 0.000 description 18
- 210000001072 colon Anatomy 0.000 description 18
- 239000000499 gel Substances 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 17
- 230000028993 immune response Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 230000000638 stimulation Effects 0.000 description 17
- 102100040247 Tumor necrosis factor Human genes 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 15
- 230000006378 damage Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 239000002158 endotoxin Substances 0.000 description 15
- 210000000987 immune system Anatomy 0.000 description 15
- 229920006008 lipopolysaccharide Polymers 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 15
- 210000000440 neutrophil Anatomy 0.000 description 15
- 238000012546 transfer Methods 0.000 description 15
- 241000701447 unidentified baculovirus Species 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 238000001890 transfection Methods 0.000 description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 13
- 206010020751 Hypersensitivity Diseases 0.000 description 13
- 208000026935 allergic disease Diseases 0.000 description 13
- 230000008901 benefit Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 201000008482 osteoarthritis Diseases 0.000 description 13
- 230000000770 proinflammatory effect Effects 0.000 description 13
- 230000028327 secretion Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 12
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 12
- 230000003321 amplification Effects 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 229920003045 dextran sodium sulfate Polymers 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- -1 that is Proteins 0.000 description 12
- 102000004890 Interleukin-8 Human genes 0.000 description 11
- 108090001007 Interleukin-8 Proteins 0.000 description 11
- 241001452677 Ogataea methanolica Species 0.000 description 11
- 238000004520 electroporation Methods 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 241000701161 unidentified adenovirus Species 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 10
- 241000699660 Mus musculus Species 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 102000003675 cytokine receptors Human genes 0.000 description 10
- 108010057085 cytokine receptors Proteins 0.000 description 10
- 229960000485 methotrexate Drugs 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 9
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 230000007815 allergy Effects 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 102000056946 human IL17F Human genes 0.000 description 9
- 210000004408 hybridoma Anatomy 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 230000028709 inflammatory response Effects 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 230000001575 pathological effect Effects 0.000 description 9
- 230000007170 pathology Effects 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000013049 sediment Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 102100033461 Interleukin-17A Human genes 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 238000012377 drug delivery Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 210000001503 joint Anatomy 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 210000005253 yeast cell Anatomy 0.000 description 8
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 210000000845 cartilage Anatomy 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000002429 large intestine Anatomy 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 101001019598 Homo sapiens Interleukin-17 receptor A Proteins 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 6
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 6
- 238000011579 SCID mouse model Methods 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- 108010022394 Threonine synthase Proteins 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 102000004419 dihydrofolate reductase Human genes 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000005550 inflammation mediator Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 210000003292 kidney cell Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000004005 microsphere Substances 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000008506 pathogenesis Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229940076788 pyruvate Drugs 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 230000036303 septic shock Effects 0.000 description 6
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 210000003371 toe Anatomy 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 108090000172 Interleukin-15 Proteins 0.000 description 5
- 102000003812 Interleukin-15 Human genes 0.000 description 5
- 108010065637 Interleukin-23 Proteins 0.000 description 5
- 102000013264 Interleukin-23 Human genes 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 206010033645 Pancreatitis Diseases 0.000 description 5
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 5
- 101710103506 Platelet-derived growth factor subunit A Proteins 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 239000013566 allergen Substances 0.000 description 5
- 230000003367 anti-collagen effect Effects 0.000 description 5
- 230000002391 anti-complement effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 108010008730 anticomplement Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- 102100039897 Interleukin-5 Human genes 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 108010025832 RANK Ligand Proteins 0.000 description 4
- 102000014128 RANK Ligand Human genes 0.000 description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000006020 chronic inflammation Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 208000010643 digestive system disease Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- 230000001185 psoriatic effect Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 210000000664 rectum Anatomy 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000036269 ulceration Effects 0.000 description 4
- 208000016261 weight loss Diseases 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102100035882 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 241000991587 Enterovirus C Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100031939 Erythropoietin Human genes 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102100033105 Interleukin-17C Human genes 0.000 description 3
- 102000003810 Interleukin-18 Human genes 0.000 description 3
- 108090000171 Interleukin-18 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 208000034486 Multi-organ failure Diseases 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 102000004140 Oncostatin M Human genes 0.000 description 3
- 108090000630 Oncostatin M Proteins 0.000 description 3
- 108091008606 PDGF receptors Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 201000009961 allergic asthma Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000002917 arthritic effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 230000008209 cardiovascular development Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 210000004921 distal colon Anatomy 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 108010074108 interleukin-21 Proteins 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 210000001322 periplasm Anatomy 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000010242 retro-orbital bleeding Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000009331 sowing Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 239000012137 tryptone Substances 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 2
- 206010060931 Adenovirus infection Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 101100437118 Arabidopsis thaliana AUG1 gene Proteins 0.000 description 2
- 101100437119 Arabidopsis thaliana AUG2 gene Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000012657 Atopic disease Diseases 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 101150029662 E1 gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 2
- 102100036509 Erythropoietin receptor Human genes 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 2
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000998181 Homo sapiens Interleukin-17B Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 2
- 102000039989 IL-17 family Human genes 0.000 description 2
- 108091069193 IL-17 family Proteins 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 102100033101 Interleukin-17B Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 2
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 108091061943 Mir-218 microRNA precursor family Proteins 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- 101000998145 Mus musculus Interleukin-17A Proteins 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 206010029379 Neutrophilia Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 102100027330 Phosphoribosylaminoimidazole carboxylase Human genes 0.000 description 2
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- 108010073443 Ribi adjuvant Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 102100034196 Thrombopoietin receptor Human genes 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 2
- 102100023132 Transcription factor Jun Human genes 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 108010044715 asialofetuin Proteins 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229920006237 degradable polymer Polymers 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000027909 hemorrhagic diarrhea Diseases 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 102000043448 human IL17RA Human genes 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006759 inflammatory activation Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000008263 liquid aerosol Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- OVHQWOXKMOVDJP-UHFFFAOYSA-N melitin Chemical compound OC1C(O)C(O)C(C)OC1OC1C(O)C(OC=2C=C3C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)=C(C=4C=CC(O)=CC=4)O3)=O)=C(O)C=2)OC(C)C1O OVHQWOXKMOVDJP-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 108091040176 miR-218 stem-loop Proteins 0.000 description 2
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 108010035774 phosphoribosylaminoimidazole carboxylase Proteins 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000008409 synovial inflammation Effects 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- QYAPHLRPFNSDNH-MRFRVZCGSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O QYAPHLRPFNSDNH-MRFRVZCGSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 101150096273 ADE2 gene Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010060921 Abdominal abscess Diseases 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241000228431 Acremonium chrysogenum Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101100325906 Bacillus subtilis (strain 168) ganA gene Proteins 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100268548 Caenorhabditis elegans apl-1 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 102100026127 Clathrin heavy chain 1 Human genes 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920001076 Cutan Polymers 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101000968532 Dictyocaulus viviparus DVA-1 polyprotein Proteins 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N Dihydroxyacetone Natural products OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- BUAKRRKDHSSIKK-IHRRRGAJSA-N Glu-Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BUAKRRKDHSSIKK-IHRRRGAJSA-N 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- CQIIXEHDSZUSAG-QWRGUYRKSA-N Gly-His-His Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 CQIIXEHDSZUSAG-QWRGUYRKSA-N 0.000 description 1
- OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101150069554 HIS4 gene Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101001125486 Homo sapiens Basic salivary proline-rich protein 1 Proteins 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101000912851 Homo sapiens Clathrin heavy chain 1 Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101500025785 Homo sapiens IL-8(6-77) Proteins 0.000 description 1
- 101001003149 Homo sapiens Interleukin-10 receptor subunit beta Proteins 0.000 description 1
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 101000741885 Homo sapiens Protection of telomeres protein 1 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102400001232 IL-8(6-77) Human genes 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010060231 Insect Proteins Proteins 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 101710199214 Interleukin-10 receptor subunit beta Proteins 0.000 description 1
- 102100033096 Interleukin-17D Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- FNYBIOGBMWFQRJ-SRVKXCTJSA-N Met-Pro-Met Chemical compound CSCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)O)N FNYBIOGBMWFQRJ-SRVKXCTJSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 101001019584 Mus musculus Interleukin-17 receptor C Proteins 0.000 description 1
- 101000998150 Mus musculus Interleukin-17F Proteins 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101100243377 Mus musculus Pepd gene Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 1
- 108010014632 NF-kappa B kinase Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 206010048886 Onychoclasis Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229920001734 PEG propionaldehyde Polymers 0.000 description 1
- 101150029183 PEP4 gene Proteins 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102100038745 Protection of telomeres protein 1 Human genes 0.000 description 1
- 102000012515 Protein kinase domains Human genes 0.000 description 1
- 108050002122 Protein kinase domains Proteins 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101150014136 SUC2 gene Proteins 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 101100111413 Thermoanaerobacter pseudethanolicus (strain ATCC 33223 / 39E) lacZ gene Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010070774 Thrombopoietin Receptors Proteins 0.000 description 1
- 102000003911 Thyrotropin Receptors Human genes 0.000 description 1
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 244000301083 Ustilago maydis Species 0.000 description 1
- 235000015919 Ustilago maydis Nutrition 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- PCBMGUSDYHYVBQ-SOOFDHNKSA-N [4-amino-2-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazol-5-yl]phosphonic acid Chemical compound P(=O)(O)(O)C=1N=C(NC1N)C1[C@H](O)[C@H](O)[C@H](O1)CO PCBMGUSDYHYVBQ-SOOFDHNKSA-N 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 229920001718 aryloxy-PEG Polymers 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036782 biological activation Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229920001743 bis-succinimidyl carbonate PEG Polymers 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 108010009297 diglycyl-histidine Proteins 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 150000002061 ecdysteroids Chemical class 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 102000053391 human F Human genes 0.000 description 1
- 108700031895 human F Proteins 0.000 description 1
- 102000044485 human IL17B Human genes 0.000 description 1
- 102000055377 human IL25 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 108010045747 interleukin 3 receptor-like molecule Proteins 0.000 description 1
- 230000013462 interleukin-17F production Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 101150086432 lacA gene Proteins 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229940098006 multigen Drugs 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 108010085336 phosphoribosyl-AMP cyclohydrolase Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000002807 pro-secretory effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 102200008075 rs5346 Human genes 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- HAEPBEMBOAIUPN-UHFFFAOYSA-L sodium tetrathionate Chemical compound O.O.[Na+].[Na+].[O-]S(=O)(=O)SSS([O-])(=O)=O HAEPBEMBOAIUPN-UHFFFAOYSA-L 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 208000025889 stromal keratitis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229920001733 tresyl monomethoxy PEG Polymers 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77217706P | 2006-02-10 | 2006-02-10 | |
| US772177P | 2006-02-10 | ||
| US78107806P | 2006-03-10 | 2006-03-10 | |
| US781078P | 2006-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2347840T3 true ES2347840T3 (es) | 2010-11-04 |
Family
ID=38895865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07863316T Active ES2347840T3 (es) | 2006-02-10 | 2007-02-09 | Il-17rcx4 soluble y procedimiento de utilizacion en la inflamacion. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7622116B2 (OSRAM) |
| EP (1) | EP1987058B1 (OSRAM) |
| JP (1) | JP2009526084A (OSRAM) |
| AT (1) | ATE467640T1 (OSRAM) |
| AU (1) | AU2007300393B2 (OSRAM) |
| CA (1) | CA2638819A1 (OSRAM) |
| DE (1) | DE602007006429D1 (OSRAM) |
| ES (1) | ES2347840T3 (OSRAM) |
| IL (1) | IL192950A0 (OSRAM) |
| WO (1) | WO2008039553A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101001871A (zh) * | 2004-06-10 | 2007-07-18 | 津莫吉尼蒂克斯公司 | 可溶性ZcytoR14、抗ZcytoR14抗体和结合伴侣以及在炎症中的使用方法 |
| CA2679588A1 (en) | 2007-03-26 | 2008-10-02 | Zymogenetics, Inc. | Soluble il-17ra/rc fusion proteins and related methods |
| AU2008266745B2 (en) * | 2007-06-20 | 2014-04-17 | Merck Sharp & Dohme Corp. | Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease |
| GB2464183A (en) * | 2008-09-19 | 2010-04-14 | Singulex Inc | Sandwich assay |
| WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| EP2810652A3 (en) * | 2009-03-05 | 2015-03-11 | AbbVie Inc. | IL-17 binding proteins |
| AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
| JP2011032170A (ja) * | 2009-07-29 | 2011-02-17 | Morinaga Milk Ind Co Ltd | ヒト細胞ｉｌ−１７産生抑制剤 |
| US20130011413A1 (en) * | 2010-02-03 | 2013-01-10 | The University Of Tokyo | Method and Pharmaceutical Composition for Treatment of Intestinal Disease |
| WO2011140484A1 (en) | 2010-05-06 | 2011-11-10 | Singulex, Inc | Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis |
| RU2535033C2 (ru) * | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
| EP2663647A4 (en) | 2011-01-14 | 2015-08-19 | Redwood Bioscience Inc | POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD |
| US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
| US11492396B2 (en) | 2015-10-27 | 2022-11-08 | UCB Biopharma SRL | Methods of treatment using anti-IL-17A/F antibodies |
| US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
| WO2020147829A1 (zh) * | 2019-01-17 | 2020-07-23 | 北京百奥赛图基因生物技术有限公司 | 人源化转基因动物 |
| BR112022002962A2 (pt) | 2019-08-16 | 2022-07-05 | Applied Molecular Transport Inc | Composições, formulações e produção e purificação de interleucina |
| CN112250764B (zh) * | 2020-10-22 | 2022-07-29 | 深圳市康瑞克生物科技有限责任公司 | 一种抗白细胞介素17a的单克隆抗体、其编码基因及应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5684032A (en) | 1994-12-13 | 1997-11-04 | Smithkline Beecham Corporation | Compounds |
| MX9707021A (es) | 1995-03-23 | 1997-11-29 | Immunex Corp | Receptor de il-7. |
| US5945511A (en) | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
| WO1999058660A1 (en) | 1998-05-12 | 1999-11-18 | Human Genome Sciences, Inc. | 97 human secreted proteins |
| US6569645B2 (en) | 1999-05-14 | 2003-05-27 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US20020177188A1 (en) | 1998-05-15 | 2002-11-28 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US6579520B2 (en) | 1998-05-15 | 2003-06-17 | Genentech, Inc. | IL-17 related mammalian cytokine polypeptides (IL-17E) |
| WO1998049307A1 (en) | 1997-05-01 | 1998-11-05 | Zymogenetics, Inc. | Mammalian cytokine-like receptor |
| US5965704A (en) | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
| DE69841140D1 (de) | 1997-09-17 | 2009-10-22 | Human Genome Sciences Inc | Interleukin-17 rezeptor-ähnliches protein |
| DK1190056T3 (da) | 1999-07-07 | 2007-07-30 | Zymogenetics Inc | Human cytokin receptor |
| US20030199041A1 (en) | 1999-07-07 | 2003-10-23 | Presnell Scott R. | Interleukin-17 receptor homologue |
| ATE519847T1 (de) | 1999-12-23 | 2011-08-15 | Genentech Inc | Il-17-homologe polypeptide und ihre therapeutische verwendung |
| US20030092881A1 (en) | 2000-05-24 | 2003-05-15 | Gorman Daniel M. | Mammalian receptor proteins; related reagents and methods |
| WO2001090357A1 (en) | 2000-05-24 | 2001-11-29 | Genesis Research & Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
| WO2002058717A2 (en) * | 2000-10-18 | 2002-08-01 | Immunex Corporation | Methods for treating rheumatoid arthritis using il-17 antagonists |
| US20040171109A1 (en) | 2000-11-10 | 2004-09-02 | Dominik Haudenschild | IL-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage |
| US20040097447A1 (en) | 2002-11-16 | 2004-05-20 | Isis Pharmaceuticals Inc. | Modulation of interleukin 22 receptor expression |
| CN101001871A (zh) | 2004-06-10 | 2007-07-18 | 津莫吉尼蒂克斯公司 | 可溶性ZcytoR14、抗ZcytoR14抗体和结合伴侣以及在炎症中的使用方法 |
| CA2596509A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor |
| WO2007038703A2 (en) * | 2005-09-28 | 2007-04-05 | Zymogenetics, Inc | Il-17a and il-17f antagonists and methods of using the same |
| US20070249533A1 (en) * | 2005-09-28 | 2007-10-25 | Levin Steven D | Il-17a and il-17f antagonists and methods of using the same |
-
2007
- 2007-02-09 AT AT07863316T patent/ATE467640T1/de active
- 2007-02-09 EP EP07863316A patent/EP1987058B1/en not_active Not-in-force
- 2007-02-09 CA CA002638819A patent/CA2638819A1/en not_active Abandoned
- 2007-02-09 US US11/673,094 patent/US7622116B2/en active Active
- 2007-02-09 AU AU2007300393A patent/AU2007300393B2/en not_active Expired - Fee Related
- 2007-02-09 JP JP2008554516A patent/JP2009526084A/ja active Pending
- 2007-02-09 DE DE602007006429T patent/DE602007006429D1/de active Active
- 2007-02-09 WO PCT/US2007/061909 patent/WO2008039553A1/en not_active Ceased
- 2007-02-09 ES ES07863316T patent/ES2347840T3/es active Active
-
2008
- 2008-07-22 IL IL192950A patent/IL192950A0/en unknown
-
2009
- 2009-10-15 US US12/580,112 patent/US8093355B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008039553A8 (en) | 2009-07-16 |
| EP1987058B1 (en) | 2010-05-12 |
| CA2638819A1 (en) | 2008-04-03 |
| DE602007006429D1 (de) | 2010-06-24 |
| ATE467640T1 (de) | 2010-05-15 |
| AU2007300393A1 (en) | 2008-04-03 |
| WO2008039553A1 (en) | 2008-04-03 |
| AU2007300393B2 (en) | 2012-05-31 |
| EP1987058A1 (en) | 2008-11-05 |
| US20100113748A1 (en) | 2010-05-06 |
| US7622116B2 (en) | 2009-11-24 |
| JP2009526084A (ja) | 2009-07-16 |
| US20070196371A1 (en) | 2007-08-23 |
| IL192950A0 (en) | 2009-02-11 |
| US8093355B2 (en) | 2012-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2347840T3 (es) | Il-17rcx4 soluble y procedimiento de utilizacion en la inflamacion. | |
| EP1931697B1 (en) | Il-17a and il-17f antagonists and methods of using the same | |
| ES2334140T3 (es) | Anticuerpos anti-il-20 y componentes de union y procedimiento de uso en antiinflamacion. | |
| ES2347657T3 (es) | Anticuerpos dirigidos contra il-22ra y asociados de union y procedimiento de uso en inflamacion. | |
| JP4903703B2 (ja) | 可溶性ＺｃｙｔｏＲ１４、抗ＺｃｙｔｏＲ１４抗体および結合相手ならびに炎症における使用方法 | |
| US7790676B2 (en) | Soluble IL-17RA/RC fusion proteins | |
| US7842665B2 (en) | IL-17A and IL-17F antagonists | |
| US20070197441A1 (en) | Truncated il-17ra soluble receptor and methods of using in inflammation | |
| ES2353117T3 (es) | Antagonistas de il-17a e il-17f y métodos de uso de los mismos antagonistas de il-17a e il-17f y métodos de uso de los mismos. | |
| US20070049524A1 (en) | Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation | |
| HK1112927B (en) | Il-17a and il-17f antagonists and methods of using the same |